|
Society for Prevention Research R13 Conference Award (R13AA025540)
|
Meeting/ Workshop
|
ACF, CDC
|
NIAAA, NCCIH, NCI, NIDA, OD/DPCPSI/OBSSR, ODP
|
Coordinate cofunding of an R13 award (total of $180,00/fiscal year from NIAAA, NIDA, NCI, NCCIH, ODP, OBSSR, CDC, ACF); as well as a research and training funding information session at the annual meeting and the Friday SPR board meeting with SPR leadership and cofunders.
|
|
Somatic Cell Genome Editing
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NCATS, NCI, NHGRI, NHLBI, NIAID, NIAMS, NIDDK, NIMH, NINDS, OD/DPCPSI/ORIP
|
The Somatic Cell Genome Editing (SCGE) program aims to develop quality tools to perform effective and safe genome editing in human patients. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. A representative from Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) plays an advisory role for the program regarding regulatory issues. The SCGE program is a member of the National Institute of Standards and Technology (NIST) Gene Editing Consortium. The SCGE program also coordinates with the DARPA Safe Genes program when appropriate.
|
|
Specificity and Quality of Influenza-Specific Antibodies
|
Research Initiative
|
FDA
|
NIAID
|
This collaboration supports the evaluation of specificity and quality of influenza-specific antibodies in human subjects that have been vaccinated or naturally infected with influenza. Specific tasks include the construction of phage display libraries, production of recombinant proteins, development of surface plasmon resonance assays and the use of these technologies to measure antibody affinity maturation.
|
|
Standardized Machine-Readable Units of Measure
|
Committee, Work group, Advisory group, or Task Force
|
IOS
|
NLM
|
Historically, the National Library of Medicine (NLM) has been at the nexus of standards needed to make clinical data flow to and from sources for clinical care, biomedical research, and epidemiologic databases. The big new research initiatives such as PCORI, Precision medicine, and the Cancer Moonshot depend heavily on efficient access to rich clinical data. A core problem of clinical data science is the prevalence of local and idiosyncratic coding systems used by individual care institutions. The major enabler of the use of big clinical Data is the standardization of the coding systems and formats (i.e. message standards) that clinical organizations use. On the coding system side, we have been developing, disseminating, and facilitating the adoption of universal standards, i.e., Unified Code for Units of Measure (UCUM) for units of measure so that clinical measures that different institutions report in different units of measure could be converted to a single unit of measure, which would simplify their use in care and research. We are working with the National Institute of Standards and Technology (NIST) to promote the use of UCUM as a replacement for ISO-8000. We have also developed a web-based open source tool to enable the conversion of units of measure to standard machine-readable format using UCUM.
|
|
Standards for Genetic Testing Report
|
Research Initiative
|
AHRQ, CDC, IOS
|
NLM, NHGRI
|
This activity aims to develop a standard reporting format for genetic variations using Logical Observation Identifiers Names and Codes (LOINC) and HL7, for electronic medical records health information exchange, and activities of the Office of the Secretary.
|
|
State Cancer Profiles
|
Resource Development
|
CDC
|
NCI
|
The objective of the State Cancer Profiles Website is to provide a system to characterize the cancer burden in a standardized manner in order to motivate action, integrate surveillance into cancer control planning, characterize areas and demographic groups, and expose health disparities. The focus is on cancer sites for which there are evidence-based control interventions. Interactive graphics and maps provide visual support for deciding where to focus cancer control efforts.
|
|
State of Illinois - Governor's Challenge
|
Committee, Work group, Advisory group, or Task Force
|
SAMHSA
|
CC
|
Outcome Measurements for Interventions to Decrease Veteran Suicide. This collaboration works to measure various outcomes for interventions to decrease suicide among US Veterans. Following this evaluation, the group will make recommendations based of their assessments.
|
|
Steering Committee Meeting for PAR 18-947. “Integrating Biospecimen Science Approaches into Clinical Assay Development”
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
FDA and NIST participate in the Steering Committee for an NCI-funded research program, “Integrating Biospecimen Science Approaches into Clinical Assay Development.” Investigators under this research program are brought together with NCI, FDA and NIST experts to review research data and progress and discuss potential collaborative activities that may include joint research projects as well as jointly prepared publications, biospecimen SOPs and best practices.
|
|
Steering Committee of the Scientific Interest Group in Glycobiology
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIGMS, NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK
|
The Steering Committee of the Scientific Interest Group in Glycobiology (GlycoSIG) is comprised of National Institutes of Health (NIH) intramural scientists and program staff as well researchers from the Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST). The committee organizes a seminar series; an annual NIH/FDA Glycosciences Research Day Meeting (averaging 250 people in attendance); and a Mentoring & Networking Luncheon for graduate students and postdoctoral fellows to meet with staff from federal agencies and learn about NIH extramural programs. The Committee also offers a Special Topics in the Glycosciences Course every other year. In addition, the GlycoSIG maintains an email list serve to distribute information on meetings, jobs, funding opportunities, and seminars. The SIG cross posts with other NIH SIG’s that share interests.
|
|
Stimulating Peripheral Activity to Relieve Conditions
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NCATS, NCCIH, NCI, NEI, NHLBI, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIMH, NINDS
|
The Stimulating Peripheral Activity to Relieve Conditions (SPARC) program seeks to accelerate development of therapeutic devices that modulate electrical activity in nerves to improve organ function. SPARC has a memorandum of understanding with Food and Drug Administration (FDA) that facilitates coordination and collaboration around common interests and goals in developing neurostimulatory devices for interrogating and elucidating peripheral autonomic and sensory control of organ function to catalyze development of more effective and minimally invasive neuromodulation therapies. SPARC is also collaborating with the FDA through an interagency agreement to support development of technologies in the CDRH/OSEL laboratories for imaging of peripheral nerves to increase understanding of nerve structure, function and neuromodulation safety.
|